Zachery R. Reichert

<i>CDK12</i>-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu et al. · JCO Precision Oncology · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +17

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study

Zachery R. Reichert, Todd M. Morgan, Gerald Li et al. · Annals of Oncology · 2022 · 201 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde et al. · New England Journal of Medicine · 2024 · 145 citations · Full text

Medicine, Oncology, Surgery +14

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors

Leslie A. Parsels, David Karnak, Joshua D. Parsels et al. · Molecular Cancer Research · 2017 · 140 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation

Dan Zhu, Satoru Osuka, Zhaobin Zhang et al. · Cancer Cell · 2018 · 103 citations · Full text

Medicine, Cancer Biology, Oncology +13